Recent Progress of Tertiary Lymphoid Structure in Prognosis and Immunotherapy of Non-small Cell Lung Cancer / 中国肺癌杂志

Lung cancer is the leading cause of cancer death, and non-small cell lung cancer (NSCLC) accounts for 85%. Immunotherapy has significantly improved the clinical prognosis of patients with NSCLC. However, because of the complexity and heterogeneousness of the tumor microenvironment, only a subset of individuals can benefit from immunotherapy. Therefore, it is necessary to explore effective predictive biomarkers for immunotherapy of NSCLC. Tertiary lymphoid structure (TLS) is an ectopic lymphoid organ that is highly similar to secondary lymphoid organs (SLO), and the presence of TLS has been found to be closely associated with a good prognosis in immunotherapy for a variety of solid tumors, including NSCLC. This article provides a review of the prognostic role of tertiary lymphoid structures in immunotherapy of NSCLC, in order to offer references for screening suitable candidates for immunotherapy of NSCLC and develop personalized and precise treatment plans.
.

Clinical effectiveness study of laparoscopic and open radical gastrectomy for gastric cancer patients / 中国医师进修杂志

Objective To investigate the clinical effectiveness of laparoscopic and open radical gastrectomy for gastric cancer patients.Methods Seventy-two gastric cancer patients who underwent laparoscopic or open radical gastrectomy were enrolled in this study.Laparoscopic radical gastrectomy group had 38 cases,open radical gastrectomy group had 32 cases.The operating time,length of incision,bleeding volume during operation,postoperative hospital stay and the level of C reactive protein were compared.Results All patients were performed operation successfully.No patient transferred open operation in laparoscopic radical gastrectomy group.No death because of operation.The patients in laparoscopic radical gastrectomy group took longer operating time,but shorter length of incision,less bleeding volume during operation,there was significant difference (P ＜ 0.05).But the number of clearing lymph nodes between two groups had no significant difference (P ＞ 0.05).Compared with open radical gastrectomy group,the patients in laparoscopic radical gastrectomy group had shorter exhaust time,early out-of-bed activity,shorter postoperative hospital stay,lower rate of complication,there was significant difference (P ＜ 0.05).The level of C reactive protein before operation had no significant difference between two groups (P ＞ 0.05),and level of C reactive protein had the tendency of improve previously and decrease lately.The level of C reactive protein in laparoscopic radical gastrectomy group was significantly lower than that in open radical gastrectomy group at the postoperative 1st,3rd,5th day[(9.33 ± 0.27) mg/L vs.(11.29 ± 0.42) mg/L,(7.16 ± 0.18) mg/L vs.(9.87±0.65) mg/L,(4.38 ±0.41) mg/Lvs.(6.97±0.51) mg/L](P＜0.05).Conclusion Laparoscopic radical gastrectomy is useful in treating gastric cancer for it's advantage of better security,better effectiveness,quicker recover and less trauma.

Relationgship of genetic polymorphisms of ERCC1 with the clinical prognosis to platin-based chemotherapy in patients with advanced non-small cell lung cancer / 肿瘤研究与临床

Objective To investigate the relationship between genetic polymorphisms of ERCC1 and survival rate in advanced non-small cell lung cancer (NSCLC) patients treated with platinum based chemotherapy.Methods A total of 204 patients with advanced NSCLC were routinely treated by platinbased chemotherapy.The polymorphic genotypes were analyzed by MALDI-TOF-MS nethod using DNA samples isolated from peripheral blood before treatment.Besides,5 ％ samples werc extracted randomly for sequencing to test the accuracy of this method.To explored the association between SNP of ERCC1 (118) and prognosis to platinum-based chemotherapy in advanced NSCLC patients.Results Among 204 patients,61 achieved partial response,116 achieved stable response,and 27 achieved progressive disease.The overall response rate was 29.9 ％ (61/204).The effective rates of patients with the ERCC1 (118) C/C genotype,C/T + T/T genotype were 24.0 ％ (29/121) and 38.6 ％ (32/83),respectively,with significant difference (P ＜ 0.05).The response rate of ERCC1 (118) C/T allele carriers was 1.992-fold than that of C/C allele carriers (95 ％ confidence interval:1.083-3.650,P =0.025).MST,1-year survival and 2-year survival rates of patients with the ERCC1 (118) C/C genotype,C/T + T/T genotype were 9.0 months,34.7 ％ (42/121) and 4.1％ (5/121) vs 12.0 months,60.2 ％ (50/83) and 12.0 ％ (10/83),respectively,with significant difference (P ＜ 0.05).Conclusions Polymorphisms of ERCC1 might be associated with overall survival period in patients with advanced NSCLC after treatment with platin-based chemotherapy,which might be the predictive markers for overall survival.